APP Pharmaceuticals Inc

APP Pharmaceuticals — H1 2008 Earnings Presentation

28 slides from APP Pharmaceuticals's earnings presentation, Jul 30, 2008

  1. Slide 1: Analyst Meeting - H1/08 Results

    Analyst Meeting - - H1/08 Results Filed by Fresenius Kabi Pharmaceuticals Holding, LLC pursuant to Rule 425 under the Securities Act of 1933 & #160; Subject Company: APP Pharmaceuticals, Inc. & #160; Commission File No.: 0-33407 July 30,

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward- looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: Fresenius Group: Financial Results

    Sales EBIT Net income Fresenius Group: Financial Results Growth at constant currency rates Growth at actual currency rates H1/08 € 5,710 m € 781 m € 212 m % % % % % %

  4. Slide 4: Fresenius Group: Double-digit Sales Growth in all Business Segments

    Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Fresenius Group: Double-digit Sales Growth in all Business Segments H1/08 US $ 5,177 m % US $ 818 m 8 % € 1,121 m 14 % € 181 m 14 % € 1,040 m 17 % € 83 m 22 % € 177 m 11 % € 9 m 0 %

  5. Slide 5: Fresenius Kabi: Update H1/08

    Fresenius Kabi: Update H1/08 - Excellent organic sales growth of 10 % - Performance of 2007 acquisitions fully in line with our expectations - Dabur Pharma: Successful conclusion of public offer allows for transaction closing in Q3/08 - APP - outstanding opportunity to achieve a leading position in

  6. Slide 6: APP Pharmaceuticals - Transaction Update

    APP Pharmaceuticals - Transaction Update - Financing package - first step of equity financing put in place - will not limit growth opportunities in other business segments - FTC filing submitted - Integration planning initiated - complementary structures → virtually no overlap - very strong cultural

  7. Slide 7: Fresenius Helios: Update H1/08

    New Krefeld hospital Fresenius Helios: Update H1/08 - Strong organic revenue growth of %* - 1.8 % EBIT margin progression in established clinics - Smooth integration of Krefeld/Hüls hospitals - ~9 % increase in hospital admissions - Krefeld hospital construction plans finalized; investment of ~ € 18

  8. Slide 8: Fresenius Vamed: Update H1/08

    Krasnodar hospital (model), Russia Fresenius Vamed: Update H1/08 - H1/08 financial results fully on track to meet 2008 guidance - Strong order intake in H1/08 - € 25 m awarded for the hospital extension in Oberndorf/Austria - € 8 m for medical technical equipment supply for 25 hospitals in Sri Lanka

  9. Slide 9: Group Financials H1/08 − Outlook 2008

    Group Financials H1/08 − Outlook 2008

  10. Slide 10: Fresenius Group: Profit and Loss Statement

    actual constant rates rates Fresenius Group: Profit and Loss Statement €m Q2/08 H1/08 H1/08 YoY Remarks Sales 2,912 5,710 2 % 9 % Organic growth: 6 % EBIT 404 781 0 % 8 % Margin: 13.7 % Interest result -83 - -167 10 % 2 % Positive currency impact, lower average rates Taxes -111 - -214 0 % - -8 % Tax

  11. Slide 11: Fresenius Kabi: Organic Sales Growth of 10 %

    H1/08 H1/07 Change Organic Growth Fresenius Kabi: Organic Sales Growth of 10 % Maximal zweizeilig, 18 pt €m Germany 0 % 2 % Europe ex Germany 16 % 7 % Asia-Pacific 24 % 27 % Latin America 84 66 27 % 9 % RoW 108 101 7 % 11 % Total sales 1,121 986 14 % 10 %

  12. Slide 12: Fresenius Kabi: Strong EBIT Growth

    H1/08 H1/07 Growth Fresenius Kabi: Strong EBIT Growth €m Total EBIT % Margin 16.1 % 16.1 % By Region: Europe 162 145 12 % Margin 21.6 % 21.5 % International 50 20 % Margin 16.1 % 16.0 % Corporate and Corporate R&D -41 -36 -14 %

  13. Slide 13: Fresenius Group: Cash Flow

    Fresenius Group: Cash Flow Q2/08 H1/08 YoY Remarks €m Cash flow 324 624 7 % Strong earnings growth Change in working capital -121 - -143 -- Operating Cash flow 203 481 -13 % Margin: 8.4 % Capex (net) -171 -332 -13 % On track for full-year guidance Cash flow 32 149 -42 % (bf. acquisitions and dividen

  14. Slide 14: Fresenius Business Segments: Financial Outlook 2008 Fully Confirmed

    Fresenius Business Segments: Financial Outlook 2008 Fully Confirmed

  15. Slide 15: Fresenius Group: Outlook 2008 Fully Confirmed

    Fresenius Group: Outlook 2008 Fully Confirmed Revenue growth in constant currency 8 - 10 % Net income growth in constant currency - - 15 % Guidance Capex ~ € 750 m

  16. Slide 16: APP Acquisition Financing: Execution Fully on Track

    APP Acquisition Financing: Execution Fully on Track in process

  17. Slide 17: Attachments

    Attachments

  18. Slide 18: Fresenius Group: Calculation of Minority Interest

    H1/08 FY/07 Fresenius Group: Overview - Calculation of Minority Interest Earnings before tax and minority interest 614 1,241 Taxes -214 -448 Minority interest, thereof -188 -383 Fresenius Medical Care net income not attributable -166 -335 to Fresenius (~64 %) Minority interest holders in Fresenius M

  19. Slide 19: Fresenius Group: Debt and Interest Ratios

    June 30, Dec 31, 2008 2007 Fresenius Group: Debt and Interest Ratios Net debt/EBITDA 3.6 3.0 2.8 2.6 2.4 2.2 2.0 1.8 3.4 3.2 Debt (€m) 5,805 5,699 Net debt (€m) 5,464 5,338 Net debt/EBITDA 2.7 2.6 EBITDA/Interest 6.0 5.5

  20. Slide 20: Fresenius Helios: Outstanding Sales Growth

    H1/08 H1/07 Growth Fresenius Helios: Outstanding Sales Growth €m Total sales 1,040 890 17 % - established clinic portfolio 945 890 5 % * - acquisitions (consolidation < 1 yr) 95 0 * growth rate on a like for like basis

  21. Slide 21: Fresenius Helios: Excellent Earnings Development

    H1/08 H1/07 Growth Fresenius Helios: Excellent Earnings Development €m Total EBIT 83 68 22 % Margin 8.0 % 7.6 % - established clinic portfolio 89 68 Margin 9.4 % 7.6 % - acquisitions (consolidation < 1 yr) -6 0

  22. Slide 22: Fresenius Vamed: Strong Sales Development

    H1/08 H1/07 Change Fresenius Vamed: Strong Sales Development €m Total sales 177 160 11 % By Division: Project business 99 87 14 % Service business 78 73 7 % * project business only ** Dec 31, 2007 Order intake * 170 84 102 % Order backlog * 573 510 12 % **

  23. Slide 23: Fresenius Vamed: EBIT Development According to Plan

    H1/08 H1/07 Change Fresenius Vamed: EBIT Development According to Plan €m Total EBIT 9 9 0 % Margin 5.1 % 5.6 % Net income 9 8 13 %

  24. Slide 24: Fresenius Kabi: Strong Sales Growth in H1/2008

    Organic H1/08 H1/07 Growth Fresenius Kabi: Strong Sales Growth in H1/2008 €m Sales 1,121 10 % By Product Segment: Infusion Therapy 529 6 % Clinical Nutrition 13 % Transfusion Technology 19 %

  25. Slide 25: Fresenius Helios: Performance Indicators

    H1/08 H1/07 Change Fresenius Helios: Performance Indicators * Clinics in Germany ** Dec 31, 2007 No. of hospitals** 60 60 - Acute clinics 40 - Postacute care clinics No. of beds** 17,460 17,192 2 % - Acute clinics 13,699 13,333 3 % - Postacute care clinics 3,761 3,859 -3 % Admissions* - Acute care (

  26. Slide 26: Fresenius Helios: Sales Impact Hospital Acquisitions

    Fresenius Helios: Sales Impact Hospital Acquisitions Acquisitions Annualized sales Hospital Oberhausen (NRW) € ~20 m consolidated as of Apr 1, 2007 Hospital Lengerich (NRW) € ~12 m consolidated as of Apr 1, 2007 Municipal hospitals, Krefeld and Hüls € ~175 m consolidated as of Dec 31, 2007 Hospital

  27. Slide 27: Fresenius Group: Key Figures According to IFRS

    H1/08 H1/08 US GAAP IFRS Fresenius Group: Key Figures According to IFRS Sales 5,710 5,719 EBIT Interest result - -167 -167 Net income Operating Cash flow 481 483 Balance sheet total 15,491 15,543 €m

  28. Slide 28: Financial Calendar

    Financial Calendar 4.11.2008 Report on 1 st -3 rd quarters Contact Birgit Grund SVP Investor Relations Fresenius SE Telephone: +49 6172 608-2485 e-mail: Birgit.Grund@fresenius.com For further information and current news: http://www.fresenius.com

APP Pharmaceuticals — H1 2008 Earnings Presentation on 6ix